SCHEMBL5523498

SCHEMBL5523498

Cc1cnc(CC(=O)c2ccccc2)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.47
RAB9A P51151 7/20 0.47
MAPT P10636 5/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
LMNA P02545 2/20 0.45
APAF1 O14727 1/20 0.45
MITF O75030 1/20 0.45
HTT P42858 1/20 0.45
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
HDAC6 Q9UBN7 1/20 0.42
KDM6B O15054 1/20 0.42
KDM4A O75164 1/20 0.42
KDM4D Q6B0I6 1/20 0.42
KDM3B Q7LBC6 1/20 0.42
HIF1AN Q9NWT6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5850214 0.98 RAB9A (0.46) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL10979014 0.76 ALDH1A1 (0.43) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL10974338 0.74 MAPT (0.41) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL14548583 0.71 MEN1 (0.50) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL4969955 0.71 RAB9A (0.47) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL4968860 0.70 GAA (0.61) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL5850180 0.70 RAB9A (0.49) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL5851393 0.69 GAA (0.59) MAPTSMN1; SMN2ALDH1A1KDM4ETDP1
SCHEMBL10986706 0.69 CTNNB1 (0.44) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL5851850 0.69 RAB9A (0.73) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213340-A1 Farnesyl protein transferase inhibitors SCHERING CORPORATION 2007-09-13 US disclosed
US-6740661-B2 TRICYCLIC IMINE CONTAINING COMPOUNDS HAVING IMIDAZOLE SUBSTITUENT; ANTITUMOR AGENTS SCHERING CORPORATION 2004-05-25 US disclosed
US-6372747-B1 ENZYME INHIBITORS AND ANTICARCINOGENIC AGENTS SCHERING CORPORATION 2002-04-16 US disclosed
EP-1140902-A1 TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2001-10-10 EP disclosed
WO-2000037459-A1 TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2000-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213340-A1 Farnesyl protein transferase inhibitors FNTB, FNTA, FDPS NPC1 53/4885RAB9A 496/4885MAPT 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.